IBRX Q3 2018 Earnings — ImmunityBio, Inc. Revenue & Financial Results | Market Cap Arena

IBRXImmunityBio, Inc.

$8B

Q3 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$31,000+287.5% YoY

Gross Profit

$31,000100.0% margin

Operating Income

-$24M-76174.2% margin

Net Income

-$24M-76241.9% margin

EPS (Diluted)

$-0.07

QoQ Revenue Growth

+675.0%

Cash Flow

Operating Cash Flow

-$18M

Free Cash Flow

-$21M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$202M

Total Liabilities

$40M

Stockholders' Equity

$162M

Cash & Equivalents

$15M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$31,000	$8,000	+287.5%
Gross Profit	$31,000	$8,000	+287.5%
Operating Income	-$24M	-$24M	+0.3%
Net Income	-$24M	-$24M	+1.4%